Cassava Sciences, Inc. Made Big Gain
Cassava Sciences, Inc. (SAVA:NASDAQ) rocketted at $7.2, a gain of 38.5%. The stock appeared on our News Catalysts scanner on Thu 02 Jan 20 at 11:55 AM in the 'RECOMMENDATION' category. From Tue 10 Dec 19, the stock recorded 57.14% Up Days and 53.33% Green Days
About Cassava Sciences, Inc. (SAVA:NASDAQ)
Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.
Top 10 Gainers:
- Inpixon (INPX:NASDAQ), 201.83%
- DPW Holdings, Inc. (DPW:NYSEMKT), 101.65%
- Synthesis Energy Systems, Inc. (SES:NASDAQ), 100%
- Pulmatrix, Inc. (PULM:NASDAQ), 88.37%
- Outlook Therapeutics, Inc. (OTLK:NASDAQ), 48.31%
- Trillium Therapeutics Inc. (TRIL:NASDAQ), 44.66%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 38.46%
- ToughBuilt Industries, Inc. (TBLT:NASDAQ), 37.45%
- Sophiris Bio, Inc. (SPHS:NASDAQ), 35.05%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 29.8%